Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q2 2023 · 10-Q
Revenue$297.49M$297.49M+24.0% vs Q2 2022 Net Income$33.20M$33.20M+123.5% vs Q2 2022 EPS Diluted$0.64$0.64+120.7% vs Q2 2022 Gross Profit$157,878,000+28.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$87,039,000+100.3% Free Cash Flowderived$51,082,000+125.5% Margins · derivedGross margin53.1%+2.0 pt vs Q2 2022
Operating margin15.7%+5.5 pt vs Q2 2022
Net margin11.2%+5.0 pt vs Q2 2022
ended Oct 1, 2022 · filed Nov 8, 2022 · 38 d after period end